Abstract |
In this double-blind, double-dummy study, 324 patients with clinical evidence of community-acquired pneumonia (CAP) or an acute exacerbation of chronic bronchitis were randomly assigned to receive 10 days' treatment with either amoxycillin/ clavulanate 875/125 mg twice daily or amoxycillin/ clavulanate 500/125 mg three times daily. At the end of therapy, clinical success rates were 92.4% for the twice daily regimen and 94.2% for the three times daily regimen. There was no statistically significant difference between treatments (p = 0.647) and the 95% confidence interval around the treatment difference indicated that the two treatments were equivalent. Treatment equivalence was also confirmed at follow-up, four weeks after the end of treatment. Both regimens were well tolerated. In conclusion, amoxycillin/ clavulanate 875/125 mg twice daily is as effective as amoxycillin/ clavulanate 500/125 mg three times daily for the treatment of community-acquired lower respiratory tract infections and could improve patient compliance.
|
Authors | A A Balgos, G Rodriguez-Gomez, R Nasnas, A A Mahasur, B P Margono, J C Tinoco-Favila, R H Sansores-Martinez, M Hassan, O Beppo, A Wongsa, A Cukier, F Vargas |
Journal | International journal of clinical practice
(Int J Clin Pract)
1999 Jul-Aug
Vol. 53
Issue 5
Pg. 325-30
ISSN: 1368-5031 [Print] India |
PMID | 10695094
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Amoxicillin-Potassium Clavulanate Combination
|
Topics |
- Adolescent
- Adult
- Aged
- Amoxicillin-Potassium Clavulanate Combination
(administration & dosage, adverse effects)
- Bronchitis
(drug therapy)
- Chronic Disease
- Community-Acquired Infections
(drug therapy)
- Double-Blind Method
- Drug Administration Schedule
- Drug Therapy, Combination
(administration & dosage, adverse effects)
- Female
- Humans
- Male
- Middle Aged
- Pneumonia
(drug therapy)
- Treatment Outcome
|